Navigation Links
StressMarq Biosciences Inc. PCT Patent Application for a Novel Antibody Therapeutic Candidate to Combat Parkinson’s Disease is Published
Date:3/9/2019

StressMarq Biosciences Inc., a research and development company specializing in manufacturing neurological and cellular stress research tools today announced the publication of its recent PCT patent application describing a potential therapeutic monoclonal antibody for Parkinson’s Disease treatment. The antibody, still at a pre-clinical stage of development, moves the company into the drug discovery field.

The antibody was shown to neutralize the ability of alpha synuclein, a key therapeutic target in Parkinson’s Disease, to generate toxic fibrils in rat primary cells. Early stage data also suggests an ability to significantly reduce Tau aggregation, a therapeutic target in Alzheimer’s Disease. Antibodies have recently gained significant interest as therapeutic agents due to their high specificity and low toxicity profiles, differentiating them from most other drug candidates such as small molecules. The PCT application describes a new situation where a therapeutic antibody candidate appears to provide neutralizing capabilities against more than one neurological disease, although all data is still pre-clinical at this time and most of the data surrounds Parkinson’s Disease.

“The situation we have is quite remarkable. While specifically targeting a complex set of alpha synuclein oligomeric forms in order to make state-of-the art research tools, we have identified an antibody that appears to have not just neutralizing capabilities, but structure-based binding to multiple disease targets. This opens up the possibility that this therapeutic antibody candidate could treat not just one, but two or more prevalent neurological diseases with similar protein fibril structures. We look forward to seeing how this exciting platform will continue to develop,” said Ariel Louwrier, President and CEO of StressMarq.

About StressMarq Biosciences Inc.

StressMarq Biosciences is Canadian privately-held corporation based in Victoria BC that specializes in the development and manufacture of high quality research tools for the academic, pharma, and biotechnology industries. Recently it has emerged as the sole world-wide manufacturer of a variety of precursor and fibrilized protein preparations including alpha, beta and gamma synuclein, tau and transthyretin - implicated in neurological diseases including Parkinson’s and Alzheimer’s Diseases. The company also develops, manufactures and sells antibodies, small molecules and ELISA kits for research purposes. Additional information can be found on StressMarq’s website at http://www.stressmarq.com

Read the full story at https://www.prweb.com/releases/stressmarq_biosciences_inc_pct_patent_application_for_a_novel_antibody_therapeutic_candidate_to_combat_parkinsons_disease_is_published/prweb16147927.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Inflection Biosciences licenses preclinical oncology programs from the CNIO
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Springer will publish lecture series with the Mathematical Biosciences Institute
4. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
5. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
6. The new Africa -- green shoots in biosciences
7. Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
8. ACEA Biosciences Introduces an Exploratory xCELLigence® RTCA S16 Instrument
9. ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.
10. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
11. Tosoh Bioscience LLC invests in Semba Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2019)... WENDELSHEIM, De. and OAKLAND, Calif. (PRWEB) , ... ... ... of autoimmune, allergy, food intolerance, and infectious disease diagnostics and automation – is ... website is an online quality control resource giving customers access to lot-specific information, ...
(Date:3/9/2019)... , ... March 08, 2019 , ... ... is pleased to announce a new initiative focused on women in the field. ... day, free program that seeks to celebrate and empower emerging female leaders in ...
(Date:3/1/2019)... ... March 01, 2019 , ... Geneious would like to ... easy alternative to Vector NTI. , Geneious Prime already has a dedicated ... from Vector NTI, so that files will be organised in Geneious in the same ...
Breaking Biology News(10 mins):
(Date:3/11/2019)... , ... March 11, 2019 , ... In this live ... to improve your clinical trial efficiency and experience. Participants will learn how to use ... IRT expertise to ensure that the simple or complex randomization scheme is properly designed ...
(Date:3/5/2019)... ... 05, 2019 , ... San Fransisko, or Sisko for short, is a German ... old to pursue a career in dressage. According to Deborah, dressage came easy ... she’d ever worked with. Unfortunately, Sisko suffered an injury while playing in his ...
(Date:2/27/2019)... ... February 26, 2019 , ... ... industrial automation and IT solutions with 140 employees on both the east and ... engineer’s license in the State of New Hampshire. Sandmaier, a senior project engineer, ...
(Date:2/22/2019)... ... February 20, 2019 , ... Ocean Tomo ... Systems. , The patents in lot 92 relate to ... used to distinguish between human users and computers through exploiting the fundamental differences ...
Breaking Biology Technology: